e11541 Background: Breast cancer treatment can be costly, but it remains unknown if charges differ between patients who die during treatment compared to survivors. The objective of this study was to assess annualized mean charges by survival status in patients with a diagnosis of breast cancer. Methods: The University of Utah Enterprise Data Warehouse was used to analyze patients ≥18 years with a diagnosis of breast cancer identified by ICD-9 code (initial diagnosis defined as index date) treated at the Huntsman Cancer institute (HCI) from 2002-2010. The HCI Tumor Registry was used to determine stage at diagnosis and other cancers. Cause and date of death was captured from the Utah Population Database. Cancer-related (CR) and non-CR charges were by ICD-9 codes from index date until death or end of the follow-up period, were weighted by the inverse probability of survival, and annualized. Generalized linear models (GLM) with gamma distribution and log link function were used to examine charges by survival status, while adjusting for baseline characteristics including demographics, stage, and comorbidities. Results: There were 1783 patients included, of which 296 (17%) died. Compared to survivors, deceased patients were older (mean age 62 vs. 56), more were diagnosed with stage IV disease (17% vs. 3%), and fewer with stage I (24% vs. 45%); all p<0.001. Mean unadjusted annualized CR charges were not different between groups (deceased $34,310 vs. alive $32,797; p=0.64), but non-CR charges were higher for deceased patients ($39,926 vs. $16,538; p<0.001). GLM results indicated deceased patients had 90% higher annualized CR charges relative to survivors (p<0.001) and higher charges for stages I, II, and III (125%, 86%, and 69%, respectively; all p<0.001). Deceased patients had 124% higher annualized non-CR charges relative to survivors (p<0.001) and higher charges for stages I, II, and III (174%, 146%, and 107%, respectively; all p<0.001). Charges did not differ between groups for stage IV patients. Conclusions: When adjusting for confounders, death was associated with higher CR and non-CR charges, except in patients with stage IV disease at diagnosis. Patients who died during treatment may have had more aggressive disease leading to higher charges.
Read full abstract